Cerdulatinib HCl

CAS No. : 1369761-01-2

Cerdulatinib HCl,1369761-01-2
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I000045
Synonyms:PRT-062070; PRT2070
Molecular Formula:C20H27N7O3S
Molecular Weight:445.54
Price:Get quote
We match the lowest price on market.

Your information is safe with us.

Purity:  >98%
Cat No:I000045
Cas No:1369761-01-2
Product-Name:Cerdulatinib HCl

Cerdulatinib HCl(cas# 1369761-01-2), also known as PRT-062070 or PRT2070, is an novel oral dual Syk/JAK inhibitor. Cerdulatinib is currently being studied in patients with genetically-defined hematologic cancers, as well as for patients who have failed therapy due to relapse or acquired mutations. 

As a dual SYK/JAK inhibitor, Cerdulatinib significantly reduces cell viability in a subset of NHL cell lines, and induces apoptosis in BCR-signaling competent NHL cell lines.

1. Clin Cancer Res. 2017 May 1;23(9):2313-2324. doi: 10.1158/1078-0432.CCR-16-1662. Epub 2016 Oct 3.

The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Blunt MD(1), Koehrer S(2), Dobson RC(1), Larrayoz M(1), Wilmore S(1), Hayman A(1), Parnell J(1), Smith LD(1), Davies A(1), Johnson PWM(1), Conley PB(3), Pandey A(3), Strefford JC(1), Stevenson FK(1), Packham G(1), Forconi F(1)(4), Coffey GP(3), Burger JA(2), Steele AJ(5).
Author information:
(1)Cancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom. (2)Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. (3)Portola Pharmaceuticals, South San Francisco, California. (4)Haematology Department at the University Hospital Southampton NHS Trust, Southampton, United Kingdom. (5)Cancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom. A.Steele@soton.ac.uk.
Purpose: B-cell receptor (BCR)-associated kinase inhibitors, such as ibrutinib, have revolutionized the treatment of chronic lymphocytic leukemia (CLL). However, these agents are not curative, and resistance is already emerging in a proportion of patients. IL4, expressed in CLL lymph nodes, can augment BCR signaling and reduce the effectiveness of BCR kinase inhibitors. Therefore, simultaneous targeting of the IL4- and BCR signaling pathways by cerdulatinib, a novel dual Syk/JAK inhibitor currently in clinical trials (NCT01994382), may improve treatment responses in patients.Experimental Design: PBMCs from patients with CLL were treated in vitro with cerdulatinib alone or in combination with venetoclax. Cell death, chemokine, and cell signaling assay were performed and analyzed by flow cytometry, immunoblotting, q-PCR, and ELISA as indicated.Results: At concentrations achievable in patients, cerdulatinib inhibited BCR- and IL4-induced downstream signaling in CLL cells using multiple readouts and prevented anti-IgM- and nurse-like cell (NLC)-mediated CCL3/CCL4 production. Cerdulatinib induced apoptosis of CLL cells, in a time- and concentration-dependent manner, and particularly in IGHV-unmutated samples with greater BCR signaling capacity and response to IL4, or samples expressing higher levels of sIgM, CD49d+, or ZAP70+ Cerdulatinib overcame anti-IgM, IL4/CD40L, or NLC-mediated protection by preventing upregulation of MCL-1 and BCL-XL; however, BCL-2 expression was unaffected. Furthermore, in samples treated with IL4/CD40L, cerdulatinib synergized with venetoclax in vitro to induce greater apoptosis than either drug alone.Conclusions: Cerdulatinib is a promising therapeutic for the treatment of CLL either alone or in combination with venetoclax, with the potential to target critical survival pathways in this currently incurable disease. Clin Cancer Res; 23(9); 2313-24. ©2016 AACR.

2. Oncotarget. 2017 Feb 21;8(8):12953-12967. doi: 10.18632/oncotarget.14588.

Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.

Guo A(1), Lu P(1), Coffey G(2), Conley P(2), Pandey A(2), Wang YL(1).
Author information:
(1)Department of Pathology, Lymphoma Translational Pathology, University of Chicago, Chicago, IL, USA. (2)Portola Pharmaceuticals, Inc., South San Francisco, CA, USA.
Ibrutinib (BTK inhibitor) has generated remarkable responses in CLL. However, the drug, to a large extent, does not cause cell death directly and does not eradicate CLL malignant clones. Inability to eradicate CLL has fostered resistance generation. Once patients become resistant, they do poorly with a median survival of 3-4 months. Novel therapeutic strategies are needed to prevent resistance, improve treatment outcome and ultimately cure the disease. Herein, we explore dual targeting of the BCR and JAK-STAT pathways with a novel single agent, cerdulatinib, which selectively inhibits both SYK (a BCR component) and JAK kinases. We demonstrated that cerdulatinib delivered potent tumor inhibition in 60 primary CLL patient samples, especially in those with poor prognostic indicators. Importantly, cerdulatinib, but not ibrutinib, is able to overcome the support of microenvironment and induces CLL cell death at clinically achievable concentrations. Notably, cerdulatinib blocked proliferation of ibrutinib-resistant primary CLL cells and of BTKC481S-transfected/ibrutinib-resistant lymphoma cells. These anti-tumor effects are well correlated with the inhibition of BCR and JAK-STAT signaling and downstream inhibition of the functions of AKT, ERK and NFκB. Collectively, our results show that simultaneous targeting of BCR and JAK-STAT pathways is a more effective strategy relative to single BTK inhibition.
Recommended Products
  • CAS No. :13375-52-5
    Product Name:


    Cat No: M065665 View details
  • CAS No. :14116-68-8
    Product Name:


    Cat No: M065666 View details
  • CAS No. :14090-52-9
    Product Name:


    Cat No: M065667 View details
  • CAS No. :13537-23-0
    Product Name:

    Phosphorus(V) trichloride difluoride

    Cat No: M065670 View details